- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03222401
Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With N. Gonorrhoeae in Healthy Males
IGHID 11705 A Randomized, Open-label, Controlled Clinical Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With Neisseria Gonorrhoeae in Healthy Male Subjects
Study Overview
Status
Conditions
Detailed Description
The study is comprised of 8 phases:
- Screening (Visits 1 and 2)
- F598 administration (Visit 3)
- Inoculation (Visit 4)
- Observation (Visits 5 - 8, as needed)
- Definitive antibiotic treatment (Visit 9)
- Test of cure (Visit 10)
- Confirmatory interaction (Visit 11)
- Final pharmacokinetic (PK)/pharmacodynamic (PD)/anti-drug antibody determination (Visit 12)
For the purposes of standardization, Day 1 of the study will be considered the day of inoculation.
During the Screening phase, prospective subjects will undergo informed consent and will be reviewed for their compatibility with the eligibility criteria. Those subjects who meet all of the Inclusion criteria and none of the Exclusion criteria will be enrolled. Following enrollment, subjects must undergo a repeat urine screen for C. trachomatis, N. gonorrhoeae and T. vaginalis (Days -17 to -4).
If the second urine screening test is negative, subjects will enter the F598 administration phase. Subjects will return to the study site and will be randomized to one of four open-label groups: Control (no treatment) or treatment with F598 at one of three doses. Following F598 administration or assignment to the Control group, subjects must return to the study site for inoculation with N. gonorrhoeae within 2 weeks. Thus, F598 will be administered on any one of Days -12 to -2.
During the inoculation phase, subjects will return to the study site and receive an inoculum of N. gonorrhoeae in the anterior urethra. A third and final urine screen for C. trachomatis, N. gonorrhoeae and T. vaginalis will be obtained immediately before inoculation.
Once subjects have been inoculated with N. gonorrhoeae, they will enter the observation phase and will return to the study site daily for up to 5 days for a physical examination (in particular, for evidence of urethral discharge) and a urine sample for evidence of infection (NAAT and culture) as well as blood for F598 PK/PD and safety labs.
The observation phase will end and definitive antibiotic therapy will be administered when any one of four criteria is met:
- The subject requests antibiotic treatment
- The subject is found to by symptomatic (discharge, urethral discomfort)
- The subject has reached Day 6 of the study
Thus, depending on the circumstances, definitive antibiotic therapy can be administered between Days 2 - 6, inclusive.
A follow-up visit at the study site will be conducted 3 - 5 days after definitive antibiotic therapy has been administered to ensure treatment response. Thus, depending on when the subject received antibiotics, this visit could occur between Days 5 - 11, inclusive. A physical examination will be performed and urine for evidence of infection (NAAT) as well as blood for F598 PK/PD will be obtained.
A confirmatory interaction with the subject will occur at the study site 7 - 10 days after the follow-up visit to confirm the subject's response and answer any questions the subject may have. Thus, depending on when the subject had his follow-up visit, the confirmatory visit could occur between Days 12 - 21, inclusive. Blood for F598 PK/PD, anti-F598 antibodies and safety labs will be obtained.
A final visit will occur approximately 8 weeks after inoculation (days 52 - 60) to obtain serum for PK/PD and anti-F598 antibodies.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- University of North Carolina at Chapel Hill
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy male between the ages of 18 and 35 years
- Able and willing to be located easily by providing street address and telephone number (land line and/or cell phone number)
- Able and willing to provide written informed consent
- Able and willing to attend all study visits and follow-up visit during the week after treatment
- Willing to abstain from masturbation during the 6 days after inoculation
- Willing to abstain from all sexual activity during the course of the study
- No clinically significant abnormalities on physical examination
- No clinically significant abnormalities in serum chemistries, hematology and urinalysis
- Urine negative for chlamydia, gonorrhea and trichomonas
- No history of sexually transmitted infections (STIs), including syphilis and hepatitis B (HBV) & hepatitis C (HCV)
- Negative human immunodeficiency virus (HIV), syphilis and HCV serologies
- Negative HBV core and surface antibodies or results consistent with immunization (negative HBV core antibody/positive HBV surface antibody)
- No history of bleeding diathesis
- No history of seizures (due to reports of seizures with ciprofloxacin)
- No history of cancer, except basal cell carcinoma of the skin more than 5 years ago
- No history of drug abuse
- No history of psychiatric disorders, except depression controlled by medication
- No history of genitourinary surgery
Exclusion Criteria:
- Student or employee under the direct supervision of any of the study investigators
- Any known immunodeficiencies including complement deficiency, antibody deficiency, chronic granulomatous disease or HIV infection
- Sickle cell disease
- Psychiatric disorders that would interfere with the ability of the subject to comply with the requirements of the protocol
- Unstable depression (defined as receiving either <3 months of the same medication (and dose) or a decompensating event during the previous 3 months) or depression that, in the opinion of the investigator, will compromise the subject's ability to comply with protocol requirements
- Heart murmur or heart disease
- Anatomic abnormality of the urinary tract
- Any antibiotic treatment in the past 30 days, or azithromycin in the past 60 days
- Chemotherapy within the past year
- Current steroid use, except for topical application
- Allergy to penicillin, cephalosporins, ciprofloxacin or to lidocaine
Treatment with medications that are contraindicated with cefixime, ceftriaxone or ciprofloxacin and that cannot be withheld for the single doses given in this study.
Medications not permitted with cefixime or ceftriaxone include:
- Warfarin
- Probenecid
- Aspirin
- Diuretics such as furosemide
- Aminoglycoside antibiotics
- Chloramphenicol
Medications not permitted with ciprofloxacin include:
- Tizanidine
- Theophylline
- Warfarin
- Glyburide
- Cyclosporine
- Probenecid
- Phenytoin
- Methotrexate
- Antacids, multivitamins, and other dietary supplements containing magnesium, calcium, aluminum, iron or zinc
- Caffeine-containing medications
- Sucralfate or didanosine chewable or buffered
- Major organ dysfunction
- Any significant pre-existing condition preventing full compliance with the study
- Infection or any serious underlying medical condition that would impair the ability of the subject to receive protocol treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: SEQUENTIAL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
NO_INTERVENTION: Control Group
Control subjects will not receive an infusion or placebo
|
|
EXPERIMENTAL: 1 mg/kg single infusion of F598
|
1 mg/kg single infusion of F598
Other Names:
|
EXPERIMENTAL: 3 mg/kg single infusion of F598
|
3 mg/kg single infusion of F598
Other Names:
|
EXPERIMENTAL: 10 mg/kg single infusion of F598
|
10 mg/kg single infusion of F598
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the efficacy of F598 in preventing an experimental urethral infection with N. gonorrhoeae
Time Frame: Through study completion, an average of two months
|
Following the inoculation of N. gonorrhoeae, assess efficacy based of the proportion of infected subjects in each treatment group
|
Through study completion, an average of two months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assess the impact of F598 on urethritis symptoms caused by N. gonorrhoeae infection
Time Frame: Up to 6 weeks
|
Urethritis signs as measured on targeted physical examination or symptoms reported by subject
|
Up to 6 weeks
|
Incidence of Treatment-Emergent Adverse Events [Safety and Immunogenicity]
Time Frame: Through study completion, an average of two months
|
Monitor the treatment-emergent adverse events, infusion-associated reactions and anti-drug antibodies following administration of F598
|
Through study completion, an average of two months
|
Pharmacokinetic evaluation by measuring change from baseline in the concentration of F598 in the blood
Time Frame: Through study completion, an average of two months
|
Cmax: Observed maximum serum concentration
|
Through study completion, an average of two months
|
Pharmacokinetic evaluation by measuring change from baseline in the concentration of F598 in the blood
Time Frame: Through study completion, an average of two months
|
Tmax: Time to attain maximum serum concentration
|
Through study completion, an average of two months
|
Pharmacokinetic evaluation by measuring change from baseline in the concentration of F598 in the blood
Time Frame: Through study completion, an average of two months
|
T 1/2: Elimination half-life
|
Through study completion, an average of two months
|
Pharmacokinetic evaluation by measuring change from baseline in the concentration of F598 in the blood
Time Frame: Through study completion, an average of two months
|
AUC: Area under the serum concentration-time curve
|
Through study completion, an average of two months
|
Pharmacokinetic evaluation by measuring change from baseline in the concentration of F598 in the blood
Time Frame: Through study completion, an average of two months
|
CL: Total body clearance of F598 from plasma
|
Through study completion, an average of two months
|
Pharmacokinetic evaluation by measuring change from baseline in the concentration of F598 in the blood
Time Frame: Through study completion, an average of two months
|
V: Volume of F598 distribution at steady state
|
Through study completion, an average of two months
|
Pharmacodynamics: Associations between the PD parameters and infection rate
Time Frame: Through study completion, an average of two months
|
Blood samples for serum bactericidal activity following administration of F598
|
Through study completion, an average of two months
|
Pharmacodynamics: Associations between the PD parameters and infection rate
Time Frame: Through study completion, an average of two months
|
Blood samples for complement fixation following administration of F598
|
Through study completion, an average of two months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Hal Landy, MD, Alopexx Pharmaceuticals, LLC
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AP-GC-201-16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neisseria Gonorrhoeae
-
Institute of Tropical Medicine, BelgiumCompletedNeisseria GonorrhoeaeBelgium
-
University of WashingtonRecruitingNeisseria Gonorrhoeae InfectionUnited States
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences InstituteCompletedNeisseria Gonorrhoeae InfectionUnited States
-
Gen-Probe, IncorporatedCompletedChlamydia Trachomatis | Neisseria Gonorrhoeae InfectionUnited States
-
Centers for Disease Control and PreventionState University of New York - Downstate Medical CenterCompletedChlamydia Trachomatis | Neisseria GonorrhoeaeUnited States
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID); Washington State...CompletedGonorrhea | Chlamydia Trachomatis | Neisseria GonorrhoeaeUnited States
-
Rush University Medical CenterNational Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaboratorsRecruitingBacterial Vaginosis | Trichomonas Vaginitis | Neisseria Gonorrheae Infection | Chlamydia Trachomatis Infection | Vaginal MicrobiomeUnited States, Kenya
-
CHU de Quebec-Universite LavalCentre de recherche du Centre hospitalier universitaire de Sherbrooke; Maisonneuve-Rosemont... and other collaboratorsCompletedHIV | Chlamydia Trachomatis | Neisseria Gonorrhoeae InfectionBenin
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingNeisseria Gonorrhoeae Infection | Asymptomatic Pharyngeal Carriage
-
University of WashingtonNational Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaboratorsActive, not recruitingHIV Infections | HIV/AIDS | Neisseria Gonorrheae Infection | Chlamydia Trachomatis Infection | Syphilis InfectionKenya
Clinical Trials on 1 mg/kg single infusion of F598
-
AM-PharmaCompleted
-
Rockefeller UniversityBrigham and Women's Hospital; Weill Medical College of Cornell University; University...CompletedHealthy | HIVUnited States, Germany
-
Rockefeller UniversityUniversity of CologneCompletedHealthy | HIVGermany, United States
-
MedImmune LLCCompletedHealthy SubjectsUnited States
-
Crucell Holland BVNational Institutes of Health (NIH); Division of Microbiology and Infectious...WithdrawnInfluenzaUnited States, Australia, Canada, France, Germany, Spain, Belgium, Bulgaria, Netherlands, Brazil, South Africa, Sweden
-
Insel Gruppe AG, University Hospital BernRecruitingAntifibrinolytic AgentsSwitzerland
-
Lpath, Inc.CompletedHealthy SubjectsUnited States
-
Bio Sidus SACompleted
-
The Netherlands Cancer InstituteBristol-Myers SquibbActive, not recruitingStage III Skin MelanomaNetherlands
-
Assistance Publique - Hôpitaux de ParisRecruitingSteroid-Dependent Nephrotic Syndrome | Steroid-Sensitive Nephrotic SyndromeFrance